Speaker
Summary
Terbium radionuclides show promise for theragnostics, where what you see is what you treat. 155Tb (T1/2 = 5.32 d, ε) appears to be one of the most prospective diagnostic radionuclides to accompany therapeutic lanthanides in the next decade due to the wide range of available production methods for 155Tb and its similar chemical properties. However, current cyclotron-produced 155Tb has suboptimal radionuclidic purity. To improve it, most of the production methods either rely on highly enriched materials (for direct production methods) or α-particle accelerators (for the previously proposed indirect method). In this work, the possibility of producing high-purity 155Tb from the monoisotopic, and therefore readily available, terbium via 159Tb(p,5n)155Dy→155Tb nuclear reaction was investigated: from irradiation of terbium targets, through separation of 155Dy, to obtaining the final 155Tb product from 155Dy decay via radiochemical separation, ready for preclinical studies.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
